Last reviewed · How we verify
AZD8835 in combination with fulvestrant
AZD8835 is a selective and potent inhibitor of the androgen receptor.
AZD8835 is a selective and potent inhibitor of the androgen receptor. Used for Hormone receptor-positive breast cancer.
At a glance
| Generic name | AZD8835 in combination with fulvestrant |
|---|---|
| Also known as | Faslodex |
| Sponsor | AstraZeneca |
| Drug class | Androgen receptor inhibitor |
| Target | Androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
AZD8835 works by blocking the androgen receptor, which is a key driver of hormone receptor-positive breast cancer. This leads to a decrease in tumor growth and proliferation.
Approved indications
- Hormone receptor-positive breast cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD8835 in combination with fulvestrant CI brief — competitive landscape report
- AZD8835 in combination with fulvestrant updates RSS · CI watch RSS
- AstraZeneca portfolio CI